EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Comparison of clopidogrel monotherapy versus prolonged DAPT based on the GRACE risk score in patients with acute coronary syndromes at high ischemic and bleeding risk: a subgroup analysis of the OPT-BIRISK randomized clinical trial

Shiyu Zhang, Jing Li, Miaohan Qiu, Yi Li, Xiaozeng Wang, Zhifang Wang, Shuhong Su, Yaojun Zhang, Aijun Liu, Yaling Han

European Journal of Pharmacology · 2025-11 · 1006 · 178151

DOI: 10.1016/j.ejphar.2025.178151 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Pharmacology, 2025-11. Verfasst von Shiyu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, Chi…. Hauptthemen laut MEDLINE: Clopidogrel, Acute Coronary Syndrome, Hemorrhage, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study assessed the effect of clopidogrel monotherapy versus extended Dual antiplatelet therapy (DAPT) on outcomes in patients with acute coronary syndromes (ACS) who have completed 9-12 months of DAPT after Percutaneous Coronary Intervention (PCI) and meet both high bleeding and high ischemia risk (birisk), stratified by Global Registry of Acute Coronary Events (GRACE) risk score. METHODS: In the OPT-BIRISK study, 7758 ACS Patients who completed 9-12 months of DAPT after PCI were randomized either to clopidogrel monotherapy or extended DAPT. This prespecified subgroup analysis categorized patients by GRACE score into intermediate-high-risk (>88) and low-risk (≤88) groups. The primary endpoint of the study was BARC 2, 3, or 5 bleeding. The key secondary endpoint was the rate of major adverse cardio-cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). FINDINGS: In low-risk patients, BARC 2, 3, or 5 bleeding occurred in 49 (2.7 %) with clopidogrel monotherapy versus 69 (3.6 %) with extended DAPT (HR 0.73, 95 % CI 0.50-1.05; p = 0.088).In intermediate-high-risk patients, clopidogrel monotherapy versus extended DAPT showed comparable BARC 2, 3, or 5 bleeding (2.3 % vs. 3.0 %; HR 0.77, 95 % CI 0.52-1.14; p = 0.8377), but significantly reduced MACCE (2.9 % vs. 4.1 %; HR 0.69, 95 % CI 0.49-0.97; p = 0.0332). In the overall trial population, there was no significant interaction between the GRACE score and treatment group for the primary or key secondary endpoints (P > 0.05 for all outcomes). CONCLUSIONS: Among birisk patients with ACS, clopidogrel monotherapy was associated with lower incidence of all bleeding events (BARC 1-5) versus extended DAPT regardless of GRACE score, but showed no significant difference in BARC 2, 3, or 5 bleeding. Moreover, it was associated with lower MACCE incidence versus extended DAPT in intermediate-high-risk groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelAcute Coronary SyndromeHemorrhagePlatelet Aggregation InhibitorsDual Anti-Platelet TherapyHumansMaleFemaleAgedMiddle AgedPercutaneous Coronary InterventionTreatment OutcomeRisk FactorsRisk Assessment

Stichwörter der Autor:innen

Acute coronary syndromesClopidogrel monotherapyGRACE risk scoreHigh ischemic and bleeding riskProlonged DAPT

Substanzen

ClopidogrelPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, China; Postgraduate Training Base of the General Hospital of Northern The…
  • State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, China.
  • Xinxiang Central Hospital, Xinxiang, China.
  • Xuzhou Cancer Hospital, Xuzhou, China.
  • Benxi Central Hospital, Benxi, China.
  • State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyaling@163.net.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Zhang, S., Li, J., Qiu, M., Li, Y., Wang, X., Wang, Z., Su, S., Zhang, Y., Liu, A., & Han, Y. (2025). Comparison of clopidogrel monotherapy versus prolonged DAPT based on the GRACE risk score in patients with acute coronary syndromes at high ischemic and bleeding risk: a subgroup analysis of the OPT-BIRISK randomized clinical trial. European Journal of Pharmacology, 1006, 178151. https://doi.org/10.1016/j.ejphar.2025.178151

Vancouver

Zhang S, Li J, Qiu M, Li Y, Wang X, Wang Z, et al. Comparison of clopidogrel monotherapy versus prolonged DAPT based on the GRACE risk score in patients with acute coronary syndromes at high ischemic and bleeding risk: a subgroup analysis of the OPT-BIRISK randomized clinical trial. European Journal of Pharmacology. 2025;1006:178151. doi:10.1016/j.ejphar.2025.178151

BibTeX
@article{Zhang2025,
  author = {Zhang, Shiyu and Li, Jing and Qiu, Miaohan and Li, Yi and Wang, Xiaozeng and Wang, Zhifang and Su, Shuhong and Zhang, Yaojun and Liu, Aijun and Han, Yaling},
  title = {Comparison of clopidogrel monotherapy versus prolonged DAPT based on the GRACE risk score in patients with acute coronary syndromes at high ischemic and bleeding risk: a subgroup analysis of the OPT-BIRISK randomized clinical trial},
  journal = {European Journal of Pharmacology},
  year = {2025},
  volume = {1006},
  pages = {178151},
  doi = {10.1016/j.ejphar.2025.178151}
}
Kostenlos starten →